Table 1 Summary of data collection
Data type | Information recorded | Time point |
|---|---|---|
Demographics | Age, gender, postcode, Indigenous status | Enrolment |
Lifestyle | Self-reported injecting drug use, self-reported alcohol in-take, self-reported housing status, self-reported reuse of a needle/syringe, self-reported prescribed opioid substitution therapy, risk of treatment disruption (including imprisonment) | Enrolment |
Clinical | Hepatitis C history, previous treatment, comorbidities, HCV genotype and RNA level, liver function tests, liver fibrosis assessment | Treatment prescription |
Treatment | DAA therapy and duration prescribed, treatment setting, type of prescriber, concurrent medication, other concurrent HCV management interventions | Treatment prescription |
Medication adherence | Self-reported adherence to therapy | Weekly during treatment course |
Quality of life | Self-reported quality of life (QoL) score (EQ-5D-5L) | 0, 3, 6, 12 and 24 months after treatment initiation |
Outcomes | HCV RNA PCR, all re-collected laboratory and imaging results, self-reported injecting drug use, | 3 months after treatment completion |